| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Stryker Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5,745.47 |
| 52 Week High | US$5,992.47 |
| 52 Week Low | US$4,663.01 |
| Beta | 0.91 |
| 1 Month Change | -1.56% |
| 3 Month Change | 5.82% |
| 1 Year Change | 11.49% |
| 3 Year Change | 13.26% |
| 5 Year Change | 60.42% |
| Change since IPO | 120.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| SYK * | MX Medical Equipment | MX Market | |
|---|---|---|---|
| 7D | -0.2% | 0% | 0% |
| 1Y | 11.5% | 0% | 0% |
Return vs Industry: SYK * exceeded the MX Medical Equipment industry which returned -1.7% over the past year.
Return vs Market: SYK * exceeded the MX Market which returned 1.8% over the past year.
Price Volatility
| SYK * volatility | |
|---|---|
| SYK * Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: SYK * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SYK *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 52,000 | Kevin Lobo | www.stryker.com |
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Stryker Corporation Fundamentals Summary
| SYK * fundamental statistics | |
|---|---|
| Market cap | Mex$2.11t |
| Earnings (TTM) | Mex$57.04b |
| Revenue (TTM) | Mex$355.75b |
37.2x
P/E Ratio6.0x
P/S RatioIs SYK * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYK * income statement (TTM) | |
|---|---|
| Revenue | US$20.96b |
| Cost of Revenue | US$7.55b |
| Gross Profit | US$13.42b |
| Other Expenses | US$10.05b |
| Earnings | US$3.36b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.84 |
| Gross Margin | 63.99% |
| Net Profit Margin | 16.03% |
| Debt/Equity Ratio | 67.1% |
How did SYK * perform over the long term?
See historical performance and comparison